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Introduction

53
Control of molting in crustaceans involves a complex interaction between the eyestalk 54 neurosecretory center, which produces inhibitory neuropeptides, such as molt-inhibiting 55 hormone (MIH) and crustacean hyperglycemic hormone (CHH), and a pair of molting glands (Y-56 organs or YOs) in the anterior cephalothorax (Chang and Mykles, 2011; Hopkins, 2012; 57 Webster, 2015) . MIH maintains the YO in the basal state during intermolt (stage C 4 ) through a 58 cyclic nucleotide second messenger pathway (Chang and Mykles, 2011; Covi et al., 2009 Covi et al., , 2012 . , 2012; Macias et al., 2015; Xu et al., 2012) . TGFβ/Smad signaling controls PTTH-100 stimulated ecdysteroidogenesis in the insect PG (Rewitz et al., 2013; Yamanaka et al., 2013) .
Moustakas
101
Disruption of activin (Actb) signaling in Drosophila blocks the metamorphic molt by preventing 102 the ecdysteroid peak by PTTH (Gibbens et al., 2011) . Activin is required for the PG to respond 103 to PTTH; animals do not molt until they have achieved a critical weight (Rewitz et al., 2013 ). An 
107
The components of the mTOR and TGF-β signaling pathways are well represented in the G.
108
lateralis YO transcriptome (Das et al., 2016) . The purpose of this study is to investigate the roles 109 of mTOR and TGF-β signaling in regulating YO ecdysteroidogenesis. ESA was used to induce 110 molting in G. lateralis. The effects of rapamycin, an mTOR inhibitor, on hemolymph
Materials and methods
120
Animals and experimental treatments
121
Adult blackback land crabs, G. lateralis, were collected in the Dominican Republic, shipped 122 via commercial air cargo to Colorado, USA, and maintained as described previously (Covi et al., 123 2010). Molting was induced by eyestalk ablation (Covi et al., 2010; MacLea et al., 2012) .
124
The effects of SB431542 and rapamycin were determined in vivo. At Day 0, intermolt G. 
Expression of mTOR signaling genes in Y-organ
137
Total RNA was isolated from YOs using TRIzol reagent (Life Technologies, Carlsbad, CA) 138 as described previously (Covi et al., 2010) . First-strand cDNA was synthesized using 2 µg total 139 RNA in a 20 µl total reaction with SuperScript III reverse transcriptase (Life Technologies) and 140 oligo-dT(20)VN primer (50 µmol/l; IDT, Coralville, IA) as described (Covi et al., 2010 
Effects SB431542 on YO ecdysteroidogenesis and gene expression
178
Intact and ESA animals were injected with SB431542 or DMSO at Day 0 and hemolymph 179 and YOs were harvested 1, 3, 7, and 14 days post-injection. There was no effect of SB431542 or 180 DMSO on hemolymph ecdysteroid titers in intact intermolt animals ( Fig. 2A) . ESA animals 181 injected with DMSO showed a significant increase in hemolymph ecdysteroid titers by 1 day 182 post-ESA; titers continued to increase as the animal progressed through the premolt stage (Fig. 183 2A). SB431542 had no effect on the initial increase in ecdysteroid titer at 1 and 3 days post-ESA, 184 paralleling the increase in the control ESA animals ( Fig. 2A) . However, ecdysteroid titers in 185 SB431542-injected ESA animals at 7 and 14 days post-injection were significantly lower than 186 those of the control ESA animals ( Fig. 2A) . The ecdysteroid titer at 14 days post-ESA was higher than that at 7 days post-ESA, which indicates some recovery from the effects of the 188 reagent ( Fig. 2A) . (Fig. 2B-F) . The means of the Gl-EF2, Rheb mRNA levels between control and SB431542 ESA animals were significantly different at 3 200 days and 7 days post-ESA (Fig. 2B, C, D) . The means of the Gl-Akt mRNA levels were 201 significantly different at 3 days post-ESA (Fig. 2E ). There were no significant differences in the 202 means of the Gl-S6k mRNA levels between control and experimental treatments at all time 203 intervals (Fig. 2F) . The transcript levels between control and experimental treatments converged 204 at 14 days post-ESA for all five genes ( Fig. 2B-F) . In intact animals, SB431542 had no effect on 205 gene expression (data not shown). 
Effects of ESA on expression of Gl-Mstn
208
Gl-myostatin-like factor (Gl-Mstn) is an activin-like member of the TGF-β family (Covi et 209 al., 2008) . It was expressed in all 11 tissues examined, including the YO (Fig. 3) . Gl-Mstn is the 210 only activin-like contig identified in the G. lateralis YO transcriptome (Das et al., 2016) . (Fig. 4C) . By 14 days post-ESA, the Gl-Mstn mRNA level was comparable to that at 224 1, 3, and 5 days post-ESA, but was significantly higher than the level at Day 0 (Fig. 4C) . (Abuhagr et al., 2014b; Mattson and Spaziani, 1986; Mattson and Spaziani, 1987 (Fig. 2C, E, F) . These data suggest that mTOR-dependent protein 237 synthesis is required for sustained ecdysteroid synthesis in both the insect and crustacean molting 238 glands.
239
In this study, rapamycin blocked YO ecdysteroidogenesis in vivo. As the YO cannot store Compared to the control, rapamycin blocked the increase in ecdysteroid titer and the effect lasted 245 for the duration of the experiment (Fig. 1) . The prolonged effect of a single injection of 246 rapamycin was probably due to the low solubility of rapamycin in aqueous solutions. A 10 mM 247 rapamycin solution in 100% DMSO was used to keep injection volumes small, so that the final 248 DMSO concentration in the hemolymph did not exceed 0.1%. DMSO at concentrations of 2% 249 and 6% can inhibit YO ecdysteroid secretion (Spaziani et al., 2001) . It is likely that much of the 250 rapamycin precipitated at the injection site and apparently took at least 2 weeks to re-dissolve.
251
The sustained release of rapamycin from the injection site inhibited YO ecdysteroidogenesis and 252 prevented, or at least delayed, the further increase in hemolymph ecdysteroid titer from Day 7 to 253 Day 14 post-ESA observed in the control animals (Fig. 1) . The higher mean and greater 254 variability in ecdysteroid titer at Day 14 post-ESA in the rapamycin-injected animals suggest that 255 the effect of the drug was beginning to dissipate as the rapamycin was being cleared from the animals (Fig. 1) . These data suggest that mTOR activity is required for YO activation and 257 increased ecdysteroid synthesis during the premolt stage. Moreover, mTOR activity appears to 258 be necessary for the transition of the YO from the activated to committed state.
259
The YO undergoes a critical change in physiological properties during the premolt period.
260
In early premolt the activated YO remains sensitive to MIH, CHH, limb autotomy factor - 
266
YO commitment appears to involve Gl-Mstn, an activin-like peptide expressed in the YO ( Fig. 3; 267 Das et al., 2016) . The increase in Gl-Mstn mRNA level coincided with YO activation during the 268 first 3 days post-ESA, followed by a large decrease at 7 days post-ESA (Fig. 4C) . Activin 269 receptor antagonist SB431542 caused a delayed decrease in hemolymph titer in ESA animals 270 between 7 and 14 days post-ESA ( Fig. 2A) . SB431542 had no effect on the initial increase in 271 hemolymph ecdysteroid titer at 1 and 3 days post-ESA, indicating that TGF-β signaling is not 272 required for YO activation. However, the delayed effect of SB431542, as well as the prolonged 273 effect of rapamycin (Fig. 1) , suggest that YO activation is prerequisite for YO commitment. The 274 prolonged effect of SB431542 was probably due to its precipitation at the injection site, as the 275 compound, like rapamycin, has low solubility in aqueous solutions. Direct targets of the activin 276 signaling pathway are the mTOR signaling genes and Gl-EF2, as SB431542 blocked the increase 277 in Gl-mTOR and Gl-Akt mRNA levels (Fig. 2C, E) and lowered Gl-Rheb and Gl-EF2 mRNA 278 levels (Fig. 2B, D) . The up-regulation of mTOR signaling genes precedes the increase in ecdysteroidogenesis of the committed YO at Day 7 post-ESA ( Fig. 2A) . These data are 280 consistent with the hypothesis that the activated YO synthesizes Gl-Mstn for the mid premolt 281 transition and a sustained constitutive increase in ecdysteroid synthesis that is mTOR-dependent. 
Conclusions
294
Three signal transduction pathways mediate two critical transitions in the molt cycle of G.
295
lateralis. A working model, which incorporates data from this study and from a previous study
296
( Abuhagr et al., 2014b) , is illustrated in Figure 5 . MIH, via cyclic nucleotide second messengers, 297 maintains the YO in the basal state (Chang and Mykles, 2011; Covi et al., 2009; Webster, 2015) .
298
The transition of the YO from the basal to the activated state is initiated by a reduction of 299 circulating MIH (Chang and Mykles, 2011) . YO activation involves mTOR-dependent protein 300 synthesis required for cellular growth and increased ecdysteroidogenic capacity, as rapamycin 301 inhibits YO ecdysteroidogenesis in vitro (Abuhagr et al., 2014b) and in vivo (Fig. 1) . A closer examination of the effects of rapamycin on hemolymph ecdysteroid titer compared to the effects 303 of ESA on mTOR signaling gene expression in control animals suggest that mTOR up regulation 304 involves both transcriptional and posttranslational mechanisms. Initial mTOR activation is likely 305 regulated post-translationally, as the YO is highly sensitive to rapamycin in vitro (Abuhagr et al., 306 2014b) and rapamycin blocked the increase in ecdysteroid titer by 1 day post-ESA ( Fig. 1) .
307
mTOR is activated by protein phosphorylation and by Rheb through inhibition of the tuberous 308 sclerosis complex (Ekim et al., 2011; Heard et al., 2014; Huang and Manning, 2008) . mTOR 309 activation was followed by increased mRNA levels of mTOR signaling genes at 3 days post-310 ESA (Fig. 2) . mTOR regulates gene expression, either directly or indirectly, by phosphorylation 311 of transcription factors, such as STAT3 (Laplante and Sabatini, 2013) . mTOR activity may also 312 be required for the transition of the YO from the activated to the committed state, as rapamycin 313 blocked or delayed the large increase in ecdysteroid titer at 14 days post-ESA (Fig. 1 ).
314
The model proposes an autocrine regulation by an activin-like peptide that drives the 315 differentiation of the YO to the committed state (Fig. 5) . A potential candidate is Gl-Mstn, which 316 is expressed in YO, muscle, and other tissues ( Fig. 3 ; Covi et al., 2008; Das et al., 2016) . The 317 timing of the peak in Gl-Mstn mRNA level (Fig. 4C ) and the SB431542-induced drop in mTOR 318 signaling gene mRNA levels at Day 3 and hemolymph ecdysteroid titer at Day 7 (Fig. 2 ) are 319 consistent with the following mechanism: (1) upon activation, the YO synthesizes and secretes 320 Gl-Mstn peptide through the combination of increased Gl-Mstn mRNA and increased mTOR-321 dependent translation; (2) Gl-Mstn peptide binds to the activin receptor, which phosphorylates 322 and activates R-Smad; and (3) R-Smad binds to Co-Smad and the transcription factor complex 323 translocates to the nucleus and sustains or up regulates genes (e.g., 324 and Gl-Akt) required for transitioning animals from stage D 0 to D 1 between 7 and 14 days post-ESA. The model is consistent with the roles of mTOR and activin/Smad signaling in regulating 326 ecdysteroidogenesis in the insect PG (Danielsen et al., 2013; Rewitz et al., 2013; Yamanaka et 327 al., 2013 
